Mdm2 and its homolog Mdm4 inhibit the function of the tumor suppressor p53. Targeted disruption of either mdm2 or mdm4 genes in mice results in embryonic lethality that is completely rescued by concomitant deletion of p53, suggesting that deletion of negative regulators of p53 results in a constitutively active p53. Thus, these mouse models offer a unique in vivo system to assay the functional significance of different p53 modifications. Phosphorylation of serine 389 in murine p53 occurs specifically after ultraviolet-light-induced DNA damage, and phosphorylation of this site enhances p53 activity both in vitro and in vivo. Recently, mice with a serine to alanine substitution at serine 389 (p53 S389A ) in the endogenous p53 locus were generated. To examine the in vivo significance of serine 389 phosphorylation during embryogenesis, we crossed these mutant mice to mice lacking mdm2 or mdm4. The p53 S389A allele did not alter the embryonic lethality of mdm2 or mdm4. Additional crosses to assay the effect of one p53 S389A allele with a p53 null allele also did not rescue the lethal phenotypes. In conclusion, the phenotypes due to loss of mdm2 or mdm4 were not even partially rescued by p53 S389A , suggesting that p53 S389A is functionally wild type during embryogenesis.
Introduction p53 serves as a sensor for DNA damage. Posttranslational modifications and stabilization of p53 occur in response to genotoxic stress, inappropriate activation of oncogenes, and a variety of other stressors (Levine, 1997; Lakin and Jackson, 1999; Lowe, 1999) . Active p53 induces cell cycle arrest or apoptosis by activating downstream genes through binding to the responsive elements in these promoters (el-Deiry et al., 1992; Pietenpol et al., 1994) . p53 contains several domains that are important for its activity as a transcription factor. The N-terminal transactivation domain interacts with a transcriptional component, p300/CBP (Avantaggiati et al., 1997; Lee et al., 1998; Shikama et al., 1999) . The central core region of p53 is the specific DNA-binding domain. This region is a hot spot for mutations in human tumors, leading to an inactivation of p53 transcriptional activity . The third domain at the C-terminus plays a role in tetramerization of p53 that enhances its sequencespecific DNA-binding activity (Miller et al., 1996) . The extreme C-terminus of p53 is believed to function as a negative regulatory domain (Hupp and Lane, 1994a, b; Pellegata et al., 1995; Wiederschain et al., 2001) . Serine 392 in human p53 (389 in mouse) is present in this region and is known to be modified only by ultraviolet (UV) radiation, but not g-radiation (IR), through phosphorylation by casein kinase II and p38 MAP kinase (Kapoor and Lozano, 1998; Lu et al., 1998; Sayed et al., 2000; Keller et al., 2001) . Biologically, this modification is known to stabilize the p53 tetramer and enhance sequence-specific DNA-binding ability of p53 through a conformational change Lane, 1994a, 1995; Sakaguchi et al., 1997) . Milne et al. (1992) reported that mutation of the C-terminal 389 serine to alanine abolished p53 growth suppressor function in culture cells. Our laboratory (Hao et al., 1996) showed that serine 389 of murine p53 is required for normal p53-mediated transcription in cell cycle-arrested cells. Recently, Achison and Hupp (2003) showed that 5-fluorouracil-induced p53-dependent cell death was correlated with enhanced phosphorylation at serine 392 of human p53. Furthermore, the serine is evolutionally conserved from bony fish to humans, further supporting its importance in regulating p53 function (Keller et al., 2001) . Thus, phosphorylation of this site is important for both p53-mediated cell cycle arrest and cell death.
In contrast, a few reports have shown little importance of serine 389 for wild-type p53 stabilization or activity in tissue culture systems (Ashcroft et al., 1999; Blattner et al., 1999; Fiscella et al., 1994; Rolley and Milner, 1994) . This discrepancy may occur from the use of different experimental designs and different cell lines as well as the use of transient overexpression systems in tissue culture. To assay the functionality of this phosphorylation event in a more physiologically relevant manner, Bruins et al. (2004) generated mice containing a serine to alanine substitution at serine 389 in the endogenous p53 locus by cre-mediated homologous recombination. The analyses of mice will extend our understanding of the functional significance of p53 serine 389 phosphorylation in vivo.
Mdm2 and its homolog, Mdm4, negatively regulate the activity of p53 (Chen et al., 1993; Shvarts et al., 1996 Shvarts et al., , 1997 . Both proteins are known to bind to p53 and suppress its activity as a transcription factor (Chen et al., 1996; Shvarts et al., 1996; Bottger et al., 1999) . Mice null for mdm2 or mdm4 exhibit embryonic lethal phenotypes that are completely rescued by concomitant deletion of p53 (Jones et al., 1995; Montes de Oca Luna et al., 1995; Parant et al., 2001; Finch et al., 2002; Migliorini et al., 2002) . These data strongly suggest that deletion of negative regulators of p53 results in a constitutively active p53 that initiates cell death (as in the case of mdm2) or cell cycle arrest (as in the case of mdm4) (de Rozieres et al., 2000; Parant et al., 2001; Chavez-Reyes et al., 2003) . Thus, these mouse models offer a unique in vivo system to test the functionality of p53 modifications.
Since serine 389 phosphorylation is important for p53-dependent cell death or cell cycle arrest in in vitro assays, we analysed the requirement of this phosphorylation event in mdm2 and mdm4 null phenotypes. We hypothesized that if phosphorylation of p53 serine 389 plays an active role in initiating cell cycle arrest or apoptosis, then introduction of the serine to alanine loss-of-function mutation in the mdm2 or mdm4 null backgrounds may rescue the early embryonic lethal phenotypes. To test this hypothesis, we crossed mice with the serine mutation to mice lacking mdm2 or mdm4. We also examined gene dosage effects of p53 by examining the effects of p53 S389A in the absence of the other p53 allele. Our data clearly show that substitution of p53 serine 389 by alanine results in a functionally wild-type p53 during embryogenesis in mdm2 or mdm4 null mice.
Results

p53
S389A is not phosphorylated after UV radiation at serine 389
Serine 389 in mouse p53 is phosphorylated by casein kinase II and p38 MAP kinase after UV radiation but not IR (Kapoor and Lozano, 1998; Lu et al., 1998; Sayed et al., 2000; Keller et al., 2001) . First, we determined if the mutant p53 S389A protein, expressed by the mouse embryonic fibroblasts (MEFs) from a mouse homozygous for the p53 S389A mutation, could not be phosphorylated at codon 389 after UV radiation. Since p53 levels are very low in normal human and mouse fibroblasts, but increase upon serum deprivation in the culture medium (Itahana et al., 2002) , p53 null, wildtype, and homozygous p53 S389A MEFs were serum starved prior to UV radiation with 10 J/m 2 . Immunostaining with a p53-specific antibody showed mostly nuclear p53 staining in cells wild type for p53 or homozygous for p53 S389A (Figure 1a) . Using a phosphoserine-specific antibody for serine 389 (Ab389), we detected nuclear staining only in p53 wild-type cells. These results show that p53 cannot be phosphorylated at serine 389 in the homozygous p53 S389A MEFs after UV treatment. In addition, p53
S389A is present at higher levels in response to serum deprivation and UV treatment and is present mainly in the nucleus, as is wild-type p53. Additionally, we labeled MEFs with [ Transcriptional activity of p53 S389A after UV radiation
To test the transcriptional activity of the p53 S389A mutant, we examined RNA expression of two well- Figure 1 Immunocytostaining (a) and immunoprecipitation (b) of MEFs to detect p53. MEFs null (1 and 4), wild type (2 and 5), and p53 S389A homozygous for p53 (3 and 6) were used for immunostaining. Panels 1-3 were stained with M19 antibody to detect p53. Panels 4-6 were stained with a phosphoserine-specific antibody for serine 389 (Ab389). (b) MEFs null, wild type, and homozygous p53 S389A after UV treatment were metabolically labeled with [ 35 S]methionine/cysteine, followed by immunoprecipitation with either a p53 antibody (FL393) or Ab389 antibody. An * denotes a nonspecific band
Function of a p53 phosphorylation mutant in vivo T Iwakuma et al characterized p53 target genes, p21 and mdm2, employing real-time reverse transcriptase (RT)-PCR. All RNA levels were standardized by glyceraldehyde-3-phosphatedehydrogenase (GAPDH) expression, and the results are shown in Figure 2 . In wild-type MEFs, the mRNA levels of p21 and mdm2 increased at 8 and 16 h after 10 J/ m 2 of UV radiation as expected. On the other hand, in the homozygous p53 S389A MEFs, delayed and impaired expression of these genes was observed under the same conditions. This result implies that the p53 S389A mutant functions as a partial loss-of-function mutation in transcriptional activation after UV radiation.
Homozygous p53
S389A alleles cannot rescue lethality due to loss of mdm2 or mdm4
Mice homozygous for the p53 S389A mutation appear normal. To determine if the p53 S389A mutation functions as a partial loss-of-function allele in vivo, we examined the genotypes of 3-week-old mice from a cross between two mdm2
S389A/S389A mice (Table 1 and Figure 3 ). In this cross, 25% of the pups are expected to be double mutant (mdm2
). However, of 88 mice genotyped, no double mutant mice were observed. The same analysis was performed for mdm4 by crossing mdm4
S389A/S389A mice to each other. Again, of 72 mice examined, none were homozygous mutant for both alleles. In both crosses, the remaining alleles segregated at the appropriate ratios (data not shown). These results suggest that p53 S389A cannot completely rescue the mdm2 and mdm4 null phenotypes as does the p53 null allele.
p53
S389A/S389A cannot even partially rescue the phenotypes due to loss of mdm2 or mdm4
The same crosses as indicated above were performed to examine if p53 S389A could partially rescue the embryonic lethal phenotypes of mdm2 or mdm4 null mice, detectable as a prolongation of embryonic survival. Abnormalities in mdm2 null embryos are seen at the blastocyst stage prior to implantation. Implantation and a decidual reaction occur, but the developing embryo is no longer viable resulting in an empty decidua devoid of embryonic cells (Montes de Oca Luna et al., 1995; Chavez-Reyes et al., 2003) . Conversely, mdm4 null mice develop until E7.5, but fail to gastrulate and do not develop further before being resorbed beginning at E9.5 (Parant et al., 2001; Finch et al., 2002; Migliorini et al., 2002) . For these reasons, the mdm2/p53 S389A crosses were analysed at E8.5 and the mdm4/p53 crosses at E9.5. In crosses between mice with the mdm2
genotype, all 38 normal E8.5 embryos were either wild type or heterozygous for mdm2 (Table 1) . A total of 10 of the decidua were empty, indicating that mdm2
S389A/S389A embryos did not survive. 
When mdm4
þ /À p53 S389A/S389A mice were crossed with each other and examined at E9.5, a significant number of abnormal embryos (16 of 54) were detected. All abnormal embryos were mdm4 null, while all normal embryos were wild type or heterozygous for mdm4 (Table 1) . Embryos wild type or heterozygous for mdm4 and homozygous for p53 S389A mutation appeared normal at E9.5 (Figure 3c ). However, embryos null for mdm4 and homozygous for p53 S389A showed abnormalities with severe growth retardation. The morphological phenotypes of the abnormal mutant mdm4
embryos were exactly the same as mdm4 (Figure 3c ). Taken together, the p53 S389A mutant behaves like wild-type p53 and does not even partially rescue the embryonic lethal phenotypes of mdm2 and mdm4 null mice in early embryogenesis.
Effect of a single p53 S389A allele on mdm2 or mdm4 null phenotypes One final test for the in vivo functionality of p53 S389A was to determine if one p53 S389A allele in the absence of the other p53 allele could rescue the phenotypes of mdm2 or mdm4 null mice. First, however, we needed to test whether p53 haploinsufficiency partially rescued the phenotypes. To address this question, we crossed mice heterozygous for mdm2 or mdm4 and wild type for p53 with mice null for both mdm2 and p53 or both mdm4 and p53 (Table 2 ). In the mdm2 cross, we observed 20 decidua at E8.5, of which 10 were empty, the expected ratio for lack of rescue. In the mdm4 cross, 10 out of 20 decidua at E9.5 had abnormal embryos, of which the phenotype was exactly the same as that observed in mdm4 null embryos homozygous for wild-type p53 (data not shown). These results indicate that the presence of only a single allele of p53 is not sufficient to rescue even partially the mdm2 or mdm4 null phenotypes.
Although a single wild-type p53 allele cannot rescue the mdm2 or mdm4 null phenotypes, one allele of p53 S389A may be able to do so. To examine a possible role of p53 S389A in the absence of the other p53 allele, we crossed mice heterozygous for mdm2 or mdm4 and null for p53 with mice heterozygous for mdm2 or mdm4 and p53 S389A/À . At 3 weeks of age, none of the offspring were mdm2 or mdm4 null and p53 S398A/À . In contrast, double null mice were born at the expected ratios, nine of 62 (14.5%) in mdm2/p53 crosses, and eight of 62 (12.9%) in mdm4/p53 crosses, as shown in Table 3 .
To determine if having one p53 S389A allele and one null allele can partially rescue the mdm2 or mdm4 null phenotypes by prolonging embryonic survival, the same Figure 3 Genotyping and embryo phenotypes. Representative PCR results of mdm4 and p53 S389A alleles (a) and mdm2 and p53 alleles (b). W, wild type; M, mutant allele. Arrows represent primers used for PCR reactions. Exons are numbered within boxes. The neo cassette is shown as neo. The sizes of the bands are shown on the right of the gel picture. In p53 S389A mice, the HinfI restriction enzyme site is lost as a result of serine to alanine mutation at codon 389. The expected fragment sizes for the wild-type allele are 282, 242, 87, and 63 bp, and for the mutant allele 524, 87, and 63 bp, the smallest of which are not shown. (c) Representative pictures of mdm4/p53 embryos at E9.5. Note that both embryos with mdm4
S389A/S389A and mdm4 À/À show abnormalities Three empty decidua were seen. c All embryos of this genotype were abnormal. All other embryos were normal Function of a p53 phosphorylation mutant in vivo T Iwakuma et al crosses were set up and embryos examined at E8.5 for mdm2/p53 and E9.5 for mdm4/p53. As shown in Table 3 , the presence of only one mutant p53 S389A allele could not rescue the mdm2 null phenotype, although complete loss of p53 does rescue the mdm2 null phenotype (four of 62, 6.5%) consistent with previously published results (Montes de Oca Luna et al., 1995) . Similar to the results with mdm2, a single p53 S389A mutant allele also failed to rescue the mdm4 null phenotype. Taken together, the data indicate that the p53 S389A allele functions as wild type during embryogenesis.
Discussion
In this study, we addressed the in vivo role of a p53 S389A mutant in early embryonic mouse development and showed that phosphorylation of serine 389 is not required for p53 function in embryogenesis. This is the first study to examine the function of the p53 phosphorylation mutant at serine 389 in vivo. Mice null for mdm2 or mdm4 exhibit embryonic lethal phenotypes that are completely rescued by concomitant deletion of p53 (Jones et al., 1995; Montes de Oca Luna et al., 1995; Parant et al., 2001; Finch et al., 2002; Migliorini et al., 2002) . Therefore, we took advantage of mdm2 or mdm4 null mice to test the in vivo role of p53 S389A by generating double mutant mice. We hypothesized that mutation of p53 at serine 389 to alanine would result in loss of some p53 functions, possibly leading to rescue of the lethal phenotypes of mdm2 or mdm4 null mice. Using this approach, one may also address the in vivo effect of other p53 mutants during embryogenesis.
Our results show that p53 does not require phosphorylation at serine 389 for functionality during embryogenesis. Also, spontaneous tumors have not been seen in 10 homozygous p53 S389A mice observed for 18 months. Since phosphorylation of serine 389 stabilizes the p53 tetramer, our data suggest that oligomerization of p53 is redundantly regulated through other phosphorylation sites, or that in vivo serine 389 phosphorylation is not necessary for this process. Despite redundant regulation of p53 activity, several reports strongly suggest the biological importance of serine 389 of p53 (Milne et al., 1992; Sakaguchi et al., 1997; Kapoor and Lozano, 1998; Lu et al., 1998; Keller et al., 2001; Furihata et al., 2002) . The discrepancy between previous results and our studies described here may be explained by the artificial overexpression of p53 in tissue culture compared with an in vivo system in which the endogenous p53 is mutated. p53 expressed at higher than physiological levels in these experimental systems may affect the experimental outcome. However, the best explanation for this discrepancy may be due to the fact that we assayed constitutive p53 function in the absence of genotoxic stress. Importantly, in this study, we focused on the in vivo function of the p53 S389A mutant under physiological conditions. Parallel studies by Bruins et al. (2004) using the same mutant mice and cells isolated from the mice showed that serine 389 plays a role only when mice and cells are exposed to a specific genotoxic stress in vivo. These results support the idea that serine 389 functions like wild-type p53 in the absence of stress and that the activity of p53 may be regulated redundantly under physiological conditions.
A growing number of studies have indicated the importance of the post-translational modifications of p53 in regulating its activity (Lakin and Jackson, 1999; Appella and Anderson, 2001) . Especially relevant to this study are other reports using in vivo mouse models to generate missense mutations at p53 phosphorylation sites by homologous recombination (Chao et al., 2000; Wu et al., 2002; Parant and Lozano, 2003; Sluss et al., 2004) . Analysis of ES cells homozygous for a p53 serine 18 to alanine mutation showed that phosphorylation at this site is required for full p53 activity after genotoxic stress such as UV or IR (Chao et al., 2000) . Recently, Sluss et al. (2004) examined the in vivo function of p53 serine 18 mutant in an mdm2 null background. This resultant mutant p53 could not rescue the mdm2 null phenotype. The analysis of MEFs with the p53 serine 23 to alanine mutation suggested that phosphorylation at this site is not required for p53 stability and activity after genotoxic stress, which differs from several previous in vitro studies overexpressing the phosphorylation mutants (Shieh et al., 1999; Unger et al., 1999; Wu et al., 2002) . These studies support the hypothesis that p53 stability and activity are redundantly regulated in physiological conditions.
We also examined the gene dosage effect of p53. p53 heterozygosity yields a partial response for apoptosis or (Clarke et al., 1993; Harvey et al., 1993; Lowe et al., 1993; Venkatachalam et al., 1998) . We therefore hypothesized that one allele of p53 S389A might result in a functional difference in our in vivo assay. Our results show that loss of one p53 allele cannot rescue the mdm2 or mdm4 null lethal phenotypes. As observed in p53 heterozygotes, one allele of p53 S389A also caused embryonic lethality in mdm2 or mdm4 null mice. These results further support our finding that the function of p53 during embryogenesis does not require phosphorylation at serine 389.
Materials and methods
Immunofluorescence detection of p53 in mouse embryonic fibroblasts
MEFs p53 null, wild type, or homozygous for the p53 S389A mutation were established using 12.5-day embryos and the cultures were maintained with DMEM containing 10% fetal bovine serum at 371C. MEFs at passage 4 grew with about 70% confluence in the labotech chamber (NUNC). To increase p53 levels and induce phosphorylation at serine 389, cells were serum starved and exposed to 10 J/m 2 of UV-C using a Stratalinker (Stratagene). At 24 h after treatment, cells were fixed and blocked prior to incubation with either M19 goat anti-p53 antibody (Santa Cruz) or rabbit anti-p53 phosphoserine 389-specific antibody, Ab389 (Kapoor and Lozano, 1998) . Signals were detected using Leica epifluorescence microscope.
Immunoprecipitation of p53 in mouse embryonic fibroblasts
MEFs p53 null, wild type, or homozygous for the p53S389A mutation were serum starved and exposed to 10 J/m 2 of UV-C using a Stratalinker (Stratagene). At 22 h after treatment, cells were metabolically labeled with [ 35 S]methionine/cysteine for 2 h. Labeled cells were lysed with CHAPS (Sigma) lysis buffer and immunoprecipitated with either FL393 rabbit anti-p53 antibody (Santa Cruz) or rabbit anti-p53 phosphoserine 389-specific antibody, Ab389. Precipitated proteins were subjected to Tris-glycine gel electrophoresis. Signals were detected by exposing to X-ray films (Kodak).
Real-time RT-PCR
MEFs wild type and homozygous for the p53 S389A mutation were grown to 80% confluence. Cells were exposed to 10 J/m 2 of UV-C and harvested at either 8 or 16 h after treatment. RNAs were prepared using the RNeasy Mini Kit (Qiagen). Reverse transcriptase reactions were performed using the First-Strand cDNA Synthesis Kit (Amersham Bioscience). Real-time PCR was performed according to the manufacturer's instructions (Applied Biosystems). Forward primer for mouse p21 was 5 0 CCTGACAGATTTCTATCACTCCA 3 0 and reverse primer was 5 0 CAGGCAGCGTATATCAGGAG 3 0 . Forward primer for mouse mdm2 was 5 0 CTCTGGACTCG GAAGATTACAGCC 3 0 and reverse primer was 5 0 CCTGTC TGATAGACTGTGACCCG 3 0 . Forward primer for mouse GAPDH was 5 0 TCACCACCATGGAGAAGGC 3 0 and reverse primer was GCTAAGCAGTTGGTGGTGCA 3 0 . Three independent experiments were carried out. Relative mRNA expression was normalized to the value of GAPDH for each reaction.
Mice
All mouse strains were maintained in a specific pathogen-free environment in our institute. Mdm2 and mdm4 heterozygous mice were generated in our laboratory (Montes de Oca Luna et al., 1995; Parant et al., 2001) . p53 S389A heterozygous mice were generated by Bruins et al. (2004) . A heterozygous p53 knockout mouse was previously established by Jacks et al. (1994) . All strains were in a mixed C57BL6 and 129SV/Ev background.
Genotypings
Tail DNAs were used for genotyping by PCR amplification. For embryo genotyping, the embryos were dissected and soaked in 15-20 ml 1 Â PCR buffer with 1% proteinase K and 1% Triton X-100 at 551C for 2 h. After heat inactivation of proteinase K, 3-5 ml of the solution was used for the PCR reaction to determine the genotype. Genotypes for mdm2, mdm4, and p53 alleles were performed according to published studies (Jacks et al., 1994; Montes de Oca Luna et al., 1995; Parant et al., 2001) . To detect the p53 S389A mutation in the mouse genome, a PCR/digestion-based assay established by Bruins et al. (2004) was used. Primers used were the following: p53IN10#2, 5 0 GGTGGTGACAGTTGTGATAATAAT 3 0 and p53ex11#2, 5 0 TTGCAGAATGGAAGGAAAGTA 3 0 . After PCR reaction, 10 ml of the products was digested with the HinfI restriction enzyme. The expected fragment sizes for the wild-type allele are 282, 242, 87, and 63 bp, and for the mutant allele 524, 87, and 63 bp. Representative examples of genotyping are shown in Figure 3a and b.
